source
- Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…
- Tyra Biosciences’ bladder cancer pill misses expected response rate in Phase 2 trialShares of Tyra Biosciences dropped about 20% after data from its Phase 2 study of a bladder cancer pill fell short of market expectations. The experimental drug, dabogratinib, is taken daily and t…